High-dose chemotherapy of solid tumours.
The use of high-dose chemotherapy (HDC) in the range requiring autologous haematopoietic stem cell support can produce very high rates of response in patients with a variety of solid tumours but it remains controversial. The solid tumour in which HDC has been most extensively studied is breast cancer, and this disease is used as a model for the current discussion. Comparisons are made with ovarian, testicular and small-cell lung cancers and random assignment trials are suggested to demonstrate and to quantitate any survival advantages associated with therapy. Further development work is indicated.
Crown
J
J
St. Vincent's Hospital, Dublin, Ireland.
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D013736:Testicular Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents